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Abstract
Aims: To compare survival and late complications between patients treated with chemoradiotherapy and radiotherapy for locally advanced cervix cancer.
Materials and methods: A Royal College of Radiologists’ audit of patients treated with radiotherapy in UK cancer centres in 2001e2002. Survival, recurrence and
late complications were assessed for patients grouped according to radical treatment received (radiotherapy, chemoradiotherapy, postoperative radiotherapy or
chemoradiotherapy) and non-radical treatment. Late complication rates were assessed using the Franco-Italian glossary.
Results: Data were analysed for 1243 patients from 42 UK centres. Overall 5-year survival was 56% (any radical treatment); 44% (radical radiotherapy); 55%
(chemoradiotherapy) and 71% (surgery with postoperative radiotherapy). Overall survival at 5 years was 59% (stage IB), 44% (stage IIB) and 24% (stage IIIB) for
women treated with radiotherapy, and 65% (stage IB), 61% (stage IIB) and 44% (stage IIIB) for those receiving chemoradiotherapy. Cox regression showed that
survival was signiﬁcantly better for patients receiving chemoradiotherapy (hazard ratio¼ 0.77, 95% conﬁdence interval 0.60e0.98; P¼ 0.037) compared with
those receiving radiotherapy taking age, stage, pelvic node involvement and treatment delay into account. The grade 3/4 late complication rate was 8%
(radiotherapy) and 10% (chemoradiotherapy). Although complications continued to develop up to 7 years after treatment for those receiving chemo-
radiotherapy, there was no apparent increase in overall late complications compared with radiotherapy alone when other factors were taken into account
(hazard ratio¼ 0.94, 95% conﬁdence interval 0.71e1.245; P¼ 0.667).
Discussion: The addition of chemotherapy to radiotherapy seems to have improved survival compared with radiotherapy alone for women treated in
2001e2002, without an apparent rise in late treatment complications.
 2010 The Royal College of Radiologists. Published by Elsevier Ltd.
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Since 1987 the incidence of cervical cancer in the UK has
fallen from around 16 to about 8 per 100 000 [1], mainly due
to the successful screening campaign [2]. However, since
2000, incidence has largely plateaued. Cancer Registry data
[1] showed around a third of women have locally advanced
disease (tumours greater than stage I) at diagnosis. Such
patients are more likely to be elderly or socio-economically
deprived [3].Author for correspondence: P. Symonds, Department of Cancer Studies &
Molecular Medicine, Level 2, Osborne Building, Leicester Royal Inﬁrmary,
Leicester LE1 5WW, UK. Tel: þ44-116-258-6294; Fax: þ44-116-258-7599.
E-mail address: paul.symonds@uhl-tr.nhs.uk (P. Symonds).
0936-6555  2010 The Royal College of Radiologists. Published by Elsevier Ltd.
doi:10.1016/j.clon.2010.06.002In the UK, patients with International Federation of
Gynecology and Obstetrics (FIGO) stage IIB to IVA tumours
are treated by radiotherapy. However, during the last 10
years, selected patients have also received concomitant
chemotherapy. This change in practice was largely due to an
unprecedented recommendation made by the US National
Cancer Institute [4], as a result of ﬁve trials [5e9] showing
a beneﬁt of chemoradiotherapy in women with cervical
cancer. A recent systematic review based on individual
patient data from all relevant trials reported an absolute
survival beneﬁt of 6% at 5 years with chemoradiotherapy
compared with the same radiotherapy alone [10]. Anec-
dotally this has been the experience of many UK clinical
oncologists, albeit with some concern regarding an
apparent increase in serious late effects [11e13].Open access under CC BY license.
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therapy on survival and late effects in practice, the Faculty of
Oncology of The Royal College of Radiologists carried out
a national audit of outcomes of patients treated in
2001e2002 using radiotherapy or chemoradiotherapy.Materials and Methods
Clinical oncology audit leads or members of the Gynae-
cology Site Oriented e-Network of the Royal College of
Radiologists from 56 National Health Service radiotherapy
units and one private centre in the UK were requested to
complete Snap-9 Professional web-based forms regarding
all appropriate patients, either diagnosed or treated
between 1 January 2001 and 31 December 2002.
Data Available
Data on patient and tumour characteristics, treatment
and outcomes were collected from 9 January until 24
December 2008. This included late complications, based on
the Franco-Italian glossary [14], which had been used in
a previous and similar national audit [15].
Patients were grouped according to treatment received:
radical radiotherapy (at least 40 Gy external beam radio-
therapy plus brachytherapy or greater than 50 Gy external
beam radiotherapy with no brachytherapy); radical che-
moradiotherapy (radical radiotherapy plus any concurrent
chemotherapy regimen); surgery plus postoperative radio-
therapy or chemoradiotherapy (any radiotherapy or che-
moradiotherapy given after any surgery provided the time
from diagnosis to the start of external beam radiotherapy
was 6 months or less), or non-radical radiotherapy (any
radiotherapy or chemoradiotherapy that did not meet the
deﬁnition of radical as outlined above). Patients with
missing treatment or survival data; FIGO stage IVB disease;
treated outside the audit time criteria; or receiving radio-
therapy only on relapse (deﬁned as greater than 6 months’
delay between diagnosis and the start of external beam
radiotherapy) were excluded from the analyses.
Deﬁnition of Outcomes
Overall survival was deﬁned as the time from diagnosis
(at initial biopsy) until death by any cause. Disease-speciﬁc
survival was deﬁned as the time from diagnosis until death
from cervical cancer. Patients alive or with unknown date of
death were censored on the date of last follow-up. Rates of
local recurrence (conﬁned to the pelvis) and distant meta-
stases (any site) were also supplied for each patient. Crude
overall (any grade) late complication rates were calculated
from individual types and grades of late complication. For
patients who experienced more than one type, the most
severe grade was used. Patients with no complications or
unknowndateof complicationswere censoredon thedateof
last follow-up. If the date of diagnosis was unknown, the
start date of external beam radiotherapy was used to calcu-
late survival time and time to late complications.Analysis
KaplaneMeier survival estimates and associated stan-
dard errors were calculated at 3 and 5 years for each
treatment group and also by stage for those receiving
radical radiotherapy or chemoradiotherapy. KaplaneMeier
estimates were also calculated for the time to late bladder
and late bowel toxicity. No formal survival analyses were
conducted for those receiving non-radical treatment, as
treatment was probably with palliative (and not curative)
intent. This was consistent with a previous national audit
[15].
The Cox proportional hazards model (overall survival) or
logistic regression model (local recurrence and distant
metastases) was used to assess whether treatment was
independently prognostic for outcome when other factors
were taken into account. Age, FIGO stage, pelvic node
involvement, size of centre, time from diagnosis until ﬁrst
radiotherapy treatment, whether or not the patient
received brachytherapy and brachytherapy dose rate were
included in univariate analyses. Those variables that were
found to be signiﬁcantly prognostic for outcome (P< 0.05)
were included in multivariate analyses together with
treatment group. If there were missing data for any of these
variables, patients were necessarily excluded from both the
univariate and multivariate analyses, further limiting the
power of these analyses.
The Cox proportional hazards model was also used to
assess whether treatment was independently prognostic
for late complications taking into account the same factors
assessed for overall survival and additional treatment-
related factors that may inﬂuence late complications (total
dose, fraction size and number of fractions of external beam
radiotherapy and duration of all radiotherapy). Variables
found to be signiﬁcantly prognostic in univariate analyses
(P< 0.05) were included in multivariate analysis together
with treatment group. Again, patients were excluded from
the univariate and multivariate analyses where data on
these variables were not available.Results
Data Available
Data were supplied on 1412 patients from 42 centres
(74%) across the UK; 33 in England, three in Scotland,
two in Wales and one in Northern Ireland. Three centres
supplied incorrect centre codes and could not be iden-
tiﬁed. The median number of patients reported per
centre was 18 (interquartile range 13e30). In total, 169
patients (12%) were excluded from the analyses because
of missing data (79); extrapelvic disease (47); treatment
outside the audit timeframe (29); radiotherapy given on
relapse (12); or because they were duplicates (2). Data
were therefore available for 1243 patients. As 168
received non-radical treatment, survival analyses are
based on 1075 patients, with a median follow-up for
living patients of 5.2 years.
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Table 1 shows the distribution of age, stage and nodal
involvement of patients according to treatment group. The
median age at the time of diagnosis ranged from 44 to 63
years. Notably, the median age of women in the radio-
therapy group (63 years) was somewhat older than in both
the chemoradiotherapy (48 years) and postoperative
radiotherapy groups (44 years). Overall, most women had
either stage II or III disease, but in the postoperative
radiotherapy group, most women (68%) had stage I disease.
Furthermore, in the chemoradiotherapy group, around two-
thirds of patients with stage I disease had stage Ib2,
compared with less than one-third of the stage I patients in
the other treatment groups. Most women in each treatment
group had no pelvic lymph node involvement, but almost
half of the women in the postoperative radiotherapy group
(45%) had involved nodes.
Treatment Characteristics
Table 2 shows that women mainly received three- or
four-ﬁeld external beam radiotherapy (40e50 Gy) and for
the radical radiotherapy and chemoradiotherapy groups
this was generally coupled with medium or high dose rate
brachytherapy. Many women in the postoperative radio-
therapy (57%) and non-radical radiotherapy (76%) groups
received no brachytherapy. Themedian time from diagnosis
to the start of external beam radiotherapy ranged from 38
days (radical chemoradiotherapy) to 71 days (postoperativeTable 1
Patient characteristics
Radical radiotherapy
(355 patients)
Radical chemoradiation
(471 patients)
Age (years)
35 13 (5%) 66 (15%)
36e50 49 (19%) 178 (41%)
51e65 85 (33%) 136 (31%)
>65 113 (43%) 56 (13%)
Unknown 95 35
Median age 62.50 48.00
Range 21e88 18e81
Stage
IA 0 0
IB* 14 (4%) 4 (1%)
IB1 30 (9%) 15 (3%)
IB2 21 (6%) 34 (7%)
IIA 26 (7%) 34 (7%)
IIB 148 (43%) 238 (51%)
IIIA 13 (4%) 14 (3%)
IIIB 81 (23%) 111 (24%)
IVA 14 (4%) 19 (4%)
Unknown 8 2
Pelvic node involvement
Not involved 224 (73%) 284 (72%)
Involved 83 (27%) 109 (28%)
Unknown 48 78
*Unspeciﬁed substage.radiotherapy), reﬂecting the obvious delay due to upfront
surgery in these women. For women receiving chemo-
radiotherapy, the vast majority received weekly cisplatin at
40 mg/m2/cycle. The median number of cycles received per
patient was ﬁve (range one to seven).
Overall and Disease-speciﬁc Survival
Overall 5-year survival was 56% (median 6.2 years;
standard error¼ 0.31 years). Further analyses were con-
ducted within patients grouped by treatment received.
However, as this was not a randomised comparison, the
effect of differential patient selection (and hence prognosis)
is unclear. At 5 years, overall survival was 44% (standard
error¼ 2.9%) for radical radiotherapy; 55% (standard
error¼ 2.6%) for radical chemoradiotherapy and 71%
(standard error¼ 3.3%) for postoperative radiotherapy
(Fig. 1a). Disease-speciﬁc survival was 54% (standard
error¼ 3.2%) for radical radiotherapy; 59% (standard
error¼ 2.6%) for radical chemoradiotherapy and 76%
(standard error¼ 3.3%) for postoperative radiotherapy
(Fig. 1b).
For women receiving radical radiotherapy and chemo-
radiotherapy, overall and disease-speciﬁc survival are also
presented by stage (Fig. 2). At 3 years, survival was 73%
(standard error¼ 6.3%), 53% (standard error¼ 4.3%) and
44% (standard error¼ 5.6%), respectively, for women with
stage IB, IIB and IIIB disease receiving radical radiotherapy
and 74% (standard error¼ 6.5%), 71% (standard error¼ 3.1%)
and 51% (standard error¼ 4.9%) for those receiving radicalRadical surgeryþ postoperative
radiotherapy (249 patients)
Non-radical treatment
(168 patients)
52 (22%) 7 (5%)
99 (42%) 32 (24%)
64 (27%) 33 (25%)
18 (8%) 60 (46%)
16 36
44.00 63.00
21e82 24e89
2 (1%) 2 (1%)
44 (18%) 12 (8%)
75 (30%) 8 (5%)
47 (19%) 5 (3%)
22 (9%) 6 (4%)
37 (15%) 36 (23%)
2 (1%) 11 (7%)
12 (5%) 43 (28%)
2 (1%) 31 (20%)
6 14
129 (55%) 85 (64%)
106 (45%) 48 (36%)
14 35
Table 2
Treatment characteristics
Radical radiotherapy
(355 patients)
Radical chemoradiotherapy
(471 patients)
Surgeryþ postoperative
radiotherapy (249 patients)
Non-radical treatment
(168 patients)
Surgery
No surgery 257 (98%) 419 (96%) 0 112 (94%)
Hysterectomy 0 1 (<1%) 204 (82%) 3 (3%)
Laparotomy 0 4 (<1%) 23 (9%) 0
Trachelectomyþ
lymphadenectomy
0 0 1 (<1%) 0
Pelvic lymphadenectomy 0 0 1 (<1%) 0
Salvage surgery 4 (2%) 13 (3%) 1 (<1%) 3 (3%)
Unspeciﬁed type 1 (<1%) 0 19 (8%) 1 (<1%)
Unknown 93 34 0 49
External radiotherapy type
No radiotherapy 0 0 0 11 (7%)
Three or four ﬁeld 276 (78%) 393 (83%) 197 (79%) 87 (52%)
Parallel opposed 21 (6%) 41 (9%) 8 (3%) 47 (28%)
Three or four ﬁeld and
parallel opposed
0 3 (1%) 0 0
Conformal radiotherapy 50 (14%) 15 (3%) 33 (14%) 13 (8%)
Parallel opposed and
conformal
0 1 (<1%) 0 2 (1%)
Unspeciﬁed type 8 (2%) 18 (4%) 11 (4%) 8 (5%)
External radiotherapy dose
No external radiotherapy 0 0 0 11 (7%)
<40 Gy 0 0 13 (5%) 70 (42%)
40e50 Gy 317 (89%) 435 (92%) 230 (92%) 87 (52%)
>50 Gy 38 (11%) 36 (8%) 6 (2%) 0
Brachytherapy
Yes 319 (90%) 448 (95%) 109 (44%) 41 (24%)
No 36 (10%) 23 (5%) 140 (56%) 127 (76%)
Brachytherapy dose rate
High 132 (38%) 151 (32%) 38 (15%) 7 (4%)
Medium 148 (42%) 208 (44%) 55 (22%) 25 (15%)
Low 39 (11%) 89 (19%) 14 (6%) 8 (5%)
No brachytherapy 36 (10%) 23 (5%) 140 (57%) 127 (76%)
Unknown 1 0 2 1
Chemoradiotherapy regimen
No chemoradiotherapy 398 (100%) 0 154 (62%) 125 (74%)
Cisplatin (single agent) 0 447 (95%) 85 (34%) 36 (21%)
Cisplatin/5-ﬂuorouracil 0 3 (1%) 8 (3%) 0
Cisplatin/methotrexate/
bleomycin
0 5 (1%) 0 3 (2%)
Carboplatin 0 11 (2%) 1 (<1%) 2 (1%)
Other 0 4 (1%) 1 (<1%) 2 (1%)
Time from diagnosis to start of external beam radiotherapy
Median (days) 48 38 71 39
Interquartile range (days) 35e66 27e52 47e97 25e58
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(standard error¼ 7.8%), 44% (standard error¼ 4.5%) and
24% (standard error¼ 5.0%), respectively, for those
receiving radical radiotherapy and 65% (standard
error¼ 7.8%), 61% (standard error¼ 3.6%) and 44% (standard
error¼ 5.1%) for those receiving radical chemoradiotherapy
(Fig. 2a). It should be noted that, in general, the results at 5
years are less reliable because of relatively low numbers ofpatients at risk. A similar pattern was observed for disease-
speciﬁc survival (Fig. 2b).
The Cox regression for overall survival included 831
patients (348 deaths) who received radical treatment and
for whom complete information on all variables included in
the model was available. Table 3 shows that overall survival
decreased with increasing age, increasing tumour stage and
presence of involved pelvic lymph nodes. Even when these
Patients at Risk
Radical RT 355 301 223 179 140 99 34
Radical CTRT 471 397 326 276 235 178 55
Surgery + RT/CTRT 249 226 195 175 149 111 37
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198 355
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Fig. 1. KaplaneMeier curves for (a) overall survival and (b) cancer-speciﬁc survival.
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was signiﬁcantly better for those receiving surgery plus
postoperative radiotherapy (hazard ratio¼ 0.44, 95%
conﬁdence interval 0.31e0.63; P< 0.001) and for patients
receiving radical chemoradiotherapy (hazard ratio¼ 0.77,
95% conﬁdence interval 0.60e0.98; P¼ 0.037) compared
with those receiving radical radiotherapy alone.Local Recurrence Rates
Local recurrence (conﬁned to the pelvis) was recorded
for all patients. Table 4 shows that most of the women in
each treatment group had no local recurrence, with crude
rates of local recurrence in the region of 20% across alltreatment groups. Logistic regression was based on 891
patients (162 recurrences) who received radical treatment
and for whom complete information was available. Table 5
shows that the risk of local recurrence was greater with
increasing stage and involved pelvic nodes increased, but
treatment received had no independent effect.Distant Metastases Rates
Distant metastases status was available for all except 31
patients across the four treatment groups. Again, the vast
majority of women did not experience anymetastases, with
the crude rate of metastases across all treatment groups in
the region of 20% (Table 4). The major sites of metastases
Patients at Risk
Stage 1b 65 60 50 45 37 24
Stage 1b 53 48 40 36 32 25
Stage 2b 148 127 94 70 58 44
Stage 2b 238 204 172 152 126 97
Stage 3b 81 60 40 33 21 15
Stage 3b 111 93 72 53 47 34
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111 93 72 53 47 34
Stage 1b - RT
Stage 1b - CTRT        
Stage 2b - RT
Stage 2b - CTRT
Stage 3b - RT
Stage 3b - CTRT
Pr
ob
ab
ilit
y
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Time (Years)
543210
Chemoradiotherapy
a
b
:puorg yparehtoidaR 35 BII egatS ;%37 BI egatS  :lavivrus raey-3 gatS :lavivrus raey-5  ;%44 BIII egatS ,% %42 BIII egatS ,%44 BII egatS ;%95 BI e
:puorgyparehtoidaromehC  ;%15 BIII egatS ,%17 BII egatS ;%47 BI egatS  :lavivrus raey-3 %44 BIII egatS ,%16 BII egatS ;%56 BI egatS :lavivrus raey-5 
:puorg yparehtoidaR  BII egatS ,%28 BI egatS  :lavivrus raey-3 lavivrus raey-5  ;%84 BIII egatS ,%36 * %23 BIII egatS ,%75 BII egatS :
:puorgyparehtoidaromehC   ;%45 BIII egatS ,%67 BII egatS ;%67 BI egatS  :lavivrus raey-3 %84 BIII egatS ,%86 BII egatS ;%96 BI egatS :lavivrus raey-5
* stneve fo srebmun wol ot eud elbamitse ton BI egats rof lavivrus raey-5
Fig. 2. KaplaneMeier curves for (a) overall survival and (b) disease-speciﬁc survival by tumour stage (radical radiotherapy and
chemoradiotherapy groups only).
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Table 3
Multivariate Cox regression analysis of overall survival
Covariate B Degrees of
freedom
P-value Hazard ratio
(95% conﬁdence interval)
Overall survival (831 patients)
Age 0.009 1 0.026 1.01 (1.00e1.02)
Stage
Stage I e e e e
Stage II 0.235 1 0.141 1.26 (0.93e1.73)
Stage IIIeIVA 0.760 1 <0.001 2.14 (1.54e2.98)
Pelvic node involvement
Not involved e e e e
Involved 0.625 1 <0.001 1.87 (1.49e2.34)
Treatment category
Radiotherapy e e e e
Chemoradiotherapy 0.267 1 0.037 0.77 (0.60e0.98)
Surgeryþ postoperative radiotherapy 0.817 1 <0.001 0.44 (0.31e0.63)
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bone. As there were more patients with unknown distant
recurrence status, logistic regression was based on 780
patients (168 metastases) who received radical treatment
and for whom complete information was available. Table 5
shows that involved pelvic lymph nodes, smaller centre size
(lower numbers of patients treated per year) and high dose
rate brachytherapy (compared with no brachytherapy)
increased the risk of metastases. However, there was no
apparent independent effect of treatment received.
Late Toxicity
The crude late complication rates were broadly similar
across all treatment groups (Table 4). Ten deaths were
attributed to late complications overall. However, none was
recorded in the radical radiotherapygroup. Themajor sites of
serious (i.e. grade 3e4) late toxicity were the vagina, bowel
and bladder (Table 4). For the chemoradiotherapy and
radiotherapy groups, the most common site of serious late
complications was the vagina (5% and 4%, respectively)
compared with only 1% of patients in the postoperative
radiotherapygroup. Threeyears after treatment, almost all of
the bowel and bladder toxicity had occurred in the radio-
therapy group, in contrast with the chemoradiotherapy
group, where only around half of the bowel toxicity and
around 60% of bladder toxicity had occurred (Fig. 3a and b).
The Cox regression of overall late complications was
based on 711 patients (369 events) who received radical
treatment and for whom complete information was avail-
able. (Table 6) shows that late toxicity increased with age
and decreased with increasing centre size. Stage, pelvic
nodal involvement and the other treatment-related factors
assessed did not independently affect late toxicity.
Discussion
This Royal College of Radiologists’ audit shows that for
patients with cervical cancer treated with curative intent in2001e2002, the 5-year survival was 56%. Predictably, the
multivariate analysis showed that stage, age and presence
of pelvic lymph node metastases were the variables that
affected survival. The use of chemoradiotherapy also
seemed to be a signiﬁcant factor in improved survival
compared with radical radiotherapy, with a hazard ratio of
0.77 (P¼ 0.037), suggesting that better survival in the che-
moradiotherapy group was not wholly due to patient
selection. This is also in line with results of a recent
systematic review of individual patient data [10] comparing
chemoradiotherapy against radiotherapy (hazard
ratio¼ 0.81). Furthermore, although chemoradiotherapy
seemed to improve survival for patients with stage IIB and
IIIB disease compared with those receiving radiotherapy,
there seemed to be little effect in women with stage IB
disease. However, this may be due to the higher proportion
of stage IB2 tumours in the chemoradiotherapy group. The
multivariate analysis also showed a signiﬁcant improve-
ment in survival for those patients receiving postoperative
radiotherapy compared with those receiving radical radio-
therapy (hazard ratio¼ 0.44, P< 0.001) with 71% survival at
5 years. This large improvement may be explained by
selection of the best prognosis patients for surgery.
The only independent prognostic factors observed for
local recurrence were stage and involved pelvic nodes, and
for distant metastases, size of centre, involved pelvic nodes
and high dose rate brachytherapy. The effect of brachy-
therapy dose rates might simply be reﬂecting that only the
best prognosis or lowest risk patients do not receive bra-
chytherapy, but the suggestion that local recurrence and
distant metastases are unaffected by the treatment received
is surprising, given the improvement in both local and
distant recurrence with chemoradiotherapy noted in
a recent systematic review [10] and the effect on survival
seen in this audit. However, local and distant recurrence
rates in the audit were around 20% compared with rates in
the region of 40e50% in the systematic review [10] andwith
FIGO data [16]. Although it is not clear if this is due to
underreporting or for other reasons, it does mean that there
Table 4
Survival, recurrence and late complication rates (with site of grade 3/4 complication)
Radical radiotherapy
(355 patients)
Radical chemoradiation
(471 patients)
Surgeryþ postoperative
radiotherapy (249 patients)
Non-radical treatment
(168 patients)
Follow-up
Median follow-up
(range in years)
5.1 (0.10e7.9) 5.2 (0.15e7.9) 5.2 (0.20e7.4) 4.8 (0.10e7.5)
Survival
Alive 157 (44%) 267 (57%) 79 (72%) e
Dead 198 (56%) 204 (43%) 70 (28%) e
Dead (due to cancer) 140 (39%) 174 (37%) 57 (23%) e
Median overall survival 3.7 years 6.4 years >7.4 years
Median cancer-speciﬁc survival 6.2 years >7.9 years >7.4 years
Local (pelvic) recurrence
No recurrence 286 (81%) 366 (78%) 218 (88%) 122 (73%)
Recurrence 69 (19%) 105 (22%) 31 (12%) 46 (27%)
Unknown 0 0 0 0
Distant metastases
No metastases 275 (81%) 339 (73%) 205 (85%) 135 (83%)
Metastases 66 (19%) 128 (27%) 36 (15%) 28 (17%)
Unknown 14 4 8 5
Overall late complications
(crude rates)
Grade 1e2 142 (43%) 200 (47%) 88 (41%) 35 (24%)
Grade 3e4 27 (8%) 44 (10%) 10 (5%) 13 (9%)
No toxicity 162 (49%) 178 (42%) 115 (54%) 97 (67%)
Unknown 24 49 36 23
Deaths 0 6 1 3
Main sites of complications
Vagina
Grade 3 11 (4%) 17 (5%) 2 (1%) 1 (1%)
Grade 4 0 0 0 0
Rectum
Grade 3 6 (2%) 10 (3%) 2 (1%) 1 (1%)
Grade 4 0 0 0 0
Colon
Grade 3 3 (<1%) 7 (1.5%) 1 (<1%) 1 (1%)
Grade 4 0 2 (<1%) 1 (<1%) 1 (1%)
Small bowel
Grade 3 1 (<1%) 3 (1%) 3 (1%) 0
Grade 4 0 2 (<1%) 0 0
Bladder
Grade 3 5 (2%) 9 (2%) 1 (<1%) 5 (4%)
Grade 4 0 0 0 0
C.L. Vale et al. / Clinical Oncology 22 (2010) 590e601 597are about 50% fewer events available for the multivariate
analyses of recurrence than for survival. Furthermore, as the
dates of recurrence were not collected, we could only
examine the effect of different factors on the rates of
recurrence and not the time to recurrence. Both of these
differences may have limited the power and sensitivity of
our multivariate analyses to reliably detect anything other
than the strongest predictors of recurrence and, therefore,
these results should be viewed with some caution.
The increase in survival with chemoradiotherapy seems
to be achieved with no apparent increase in overall late
toxicity, although there may again be an issue with power.
Therewere six deaths attributed to late complications in the
chemoradiotherapy group, including four due to late bowelcomplications, and none in the radiotherapy group. The
bowel may be inﬁltrated and ﬁxed by the tumour predis-
posing it to perforation during or after radiotherapy. This
may be exacerbated in the chemoradiotherapy patients,
where there is a greater response to treatment. Alterna-
tively, there may be an additive effect of the chemotherapy
on the vasculature of the bowel. The most common site of
serious late complications was the vagina. If the vagina is
heavily involved with tumour, as is often the case with
advanced disease, healing will be with ﬁbrosis leading to
stenosis. The incidence of serious late complications in the
postoperative group was less than expected, possibly
reﬂecting the fact that only 44% of this group received
brachytherapy. Although almost half the patients included
Table 5
Multivariate logistic regression analysis of local recurrence and distant metastases
Covariate B Degrees of
freedom
P-value Hazard ratio
(95% conﬁdence interval)
Local recurrence (891 patients)
Age 0.000 1 0.783 1.00 (0.999e1.001)
Stage
Stage I e e e e
Stage II 0.524 1 0.058 1.689 (0.983e2.902)
Stage IIIeIVA 1.063 1 <0.001 2.894 (1.619e5.174)
Pelvic node involvement
Not involved e e e e
Involved 0.471 1 0.012 1.601 (1.110e2.311)
Time from diagnosis to start of external beam radiotherapy 0.005 1 0.117 0.995 (0.988e1.001)
Treatment category
Radiotherapy e e e e
Chemoradiotherapy 0.010 1 0.960 0.990 (0.657e1.490)
Surgeryþ postoperative radiotherapy 0.220 1 0.465 0.802 (0.444e1.448)
Distant metastases (780 patients)
Age 0.004 1 0.568 1.004 (0.990e1.019)
Stage
Stage I e e e e
Stage II 0.066 1 0.805 0.936 (0.555e1.579)
Stage IIIeIVA 0.404 1 0.170 1.498 (0.841e2.667)
Pelvic node involvement
Not involved e e e e
Involved 1.124 1 <0.001 3.076 (2.0374e4.561)
Time from diagnosis to start of external beam radiotherapy 0.006 1 0.080 0.994 (0.987e1.001)
Centre size 0.011 1 <0.001 0.989 (0.986e0.993)
Brachytherapy dose rate
No brachytherapy e e e e
Low/medium dose rate 0.369 1 0.249 1.446 (0.772e2.708)
High dose rate 0.994 1 0.003 2.703 (1.416e5.159)
Treatment category
Radiotherapy e e e e
Chemoradiotherapy 0.031 1 0.906 1.032 (0.618e1.722)
Surgeryþ postoperative radiotherapy 0.167 1 0.632 0.846 (0. 427e1.676)
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records, where only the recording of serious morbidity has
been found to be reliable [17]. It is therefore possible that
grade 1e2 late complications are under-represented [18].
Interestingly, these results seem to suggest reduced levels
of late complications (and metastases) in the larger radio-
therapy centres. Our exploratory analyses (data not shown)
seem to support the current guidance of the Royal College of
Radiologists that centres should aim to treat at least 50
patients with gynaecological malignancies per year using
brachytherapy.
The time frame of treatment and diagnosis for this audit
should provide sufﬁcient follow-up to allow for the devel-
opment of any late complications, and there does seem to
be a difference in the time to development of late compli-
cations between the treatment groups. In the radiotherapy
group, the vast majority of late bowel and bladder compli-
cations occurred within the ﬁrst 3 years after treatment.However, in the chemoradiotherapy group, complications
seem to still be developing up to 7 years after treatment.
Few of the randomised trials have reported late treatment
complications after chemoradiotherapy and indeed a recent
systematic review of individual patient data from all rand-
omised trials [10] could not formally assess the effect of
treatment on late toxicity due to the lack of data available.
Using UK Cancer Registry data, we estimate 1800e2000
eligible cases of cervical cancer during the audit timeframe.
We obtained data for 1412 women, consistent with three-
quarters of all centres having participated. However, around
12% of these were excluded from all of the analyses, with up
to an additional 364 patients being excluded from the
multivariate analyses, due to missing outcome or baseline
data. Clearly, we cannot be certain how exclusion of these
patients or those from centres not participating in the audit
might affect these results, but certainly their omission may
introduce bias.
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Fig. 3. KaplaneMeier curves for (a) late bowel toxicity and (b) overall late bladder toxicity.
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national audit of patients treated in 1993 by radiotherapy
[15], where the 5-year survival for all patients was 47%.
Thus, in the 8 years between these two audits, there has
been a potential 9% improvement in 5-year survival. Overall
survival during this period also seems to have improved for
patients with locally advanced disease, particularly those
receiving chemoradiotherapy. In 2001e2002, radiotherapy
or chemoradiotherapy would have been the preferred
treatment for most women, except those eligible for radical
surgery, with extrapelvic spread (stage IVB), the very frail or
elderly. However, practice was changing at that time.
Although some centres had begun to use chemo-
radiotherapy, many were still using radiotherapy alone,
largely because it could be given in the outpatient setting.
Survival for stage IIIB was 23% in 1993 compared with 44%
for those receiving chemoradiotherapy in 2001e2002.Similarly, 5-year survival for stage IIB disease was 47% in
1993 compared with 63% after chemoradiotherapy in
2001e2002. However, comparisons of survival between
1993 and 2001e2002 should be interpreted with caution
due to somewhat limited data at 5 years. Also, since 1993,
more sophisticated radiology, including computed tomog-
raphy and magnetic resonance imaging scanning, has
resulted in improved diagnosis of stage IVB disease,
resulting in more of the poorest prognosis patients being
excluded from the current audit. The patient groups within
the two audit series also differ. For example, women treated
with chemoradiotherapy or postoperative radiotherapy in
2001e2002 were younger, and those receiving radio-
therapywere older at the time of diagnosis than those in the
1993 series. Furthermore, in 1993, 46.1% of women had
stage IAeIIA disease, compared with only 19% (chemo-
radiotherapy) and 27% (radiotherapy) in 2001e2002. This is
Table 6
Multivariate Cox regression analysis of overall late complications
Covariate B Degrees of freedom P-value Hazard ratio (95% conﬁdence interval)
Overall late toxicity (711 patients)
Age 0.010 1 0.012 1.010 (1.002e1.019)
Stage
Stage I e e e e
Stage II 0.027 1 0.848 1.028 (0.776e1.360)
Stage IIIeIVA 0.014 1 0.934 0.986 (0.703e1.383)
Pelvic node involvement
Not involved e e e e
Involved 0.153 1 0.200 1.166 (0.922e1.474)
Centre size 0.002 1 0.004 0.998 (0.996e0.999)
Total dose of external radiotherapy 0.018 1 0.171 1.018 (0.992e1.045)
Dose per fraction (external radiotherapy) 0.406 1 0.258 0.666 (0.329e1.347)
Brachytherapy dose rate
No brachytherapy e e e e
Low/medium dose rate 0.297 1 0.108 1.345 (0.937e1.932)
High dose rate 0.243 1 0.218 1.275 (0.866e1.875)
Treatment category
Radiotherapy e e e e
Chemoradiotherapy 0.062 1 0.667 0.940 (0.710e1.245)
Surgeryþ postoperative radiotherapy 0.206 1 0.270 0.814 (0.565e1.173)
C.L. Vale et al. / Clinical Oncology 22 (2010) 590e601600probably because patients with lower stage disease are now
more commonly treated with surgery.
The treatmentof locallyadvanced cervical cancer remains
a challenge. Current experimental approaches include the
addition of hypoxic cell sensitisers, such as tirapazamine, or
inhibitors of angiogenesis, such as bevacizumab, to chemo-
radiotherapy. However, the results of this audit show that
when compared with radiotherapy alone, concomitant
chemoradiotherapy (mainlyweekly cisplatin) seems to have
improved survival of womenwith locally advanced disease.
Wider experience and increased use of chemoradiotherapy
in the UK since 2002 may further improve survival for
women with locally advanced cervical cancer.
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